What’s Happening with Cannabis Reform in Asia?


Marguerite Arnold

January 8th, 2019

Policy


It has taken a few years for cannabis reform to begin to enter Asia. However, momentum is clearly picking up.

In the middle of December 2018, New Zealand announced its plans to legalize recreational use in 2020 during the country’s general election. As such, the country may well become the third country in the world (after Uruguay and Canada) to fully legalize the drug (although Luxembourg might yet pip the Ozzies to the post).

The news is also clearly already having a domino effect regionally and was not the only intriguing canna news out of Asia in December. South Korea moved to legalize medical use literally days before New Zealand’s announcement, although this will probably be an import led market in its early days. It is also not expected that the market here will liberalize dramatically. In fact, as of October, the government even issued warnings to its citizens about consuming cannabis on visits abroad (most notably Canada). South Korea’s decision was clearly influenced in turn by the stated intent of Thailand earlier in the year to also move forward on medical reform. And on Christmas Day, in fact, the Thai government finally voted to legalize medical production and even more intriguingly, export the same (along with Israel).

Malaysia is also expected to follow suit, with government ministers beginning to explore the idea of medical reform as of last fall.

The green tide is clearly turning if not rising, finally in Asia.

The big question that still remains? When will China move? The great, green slumbering giant has begun to allow farmers to produce hemp industrially again. No matter what its Asian neighbours do, this one country, with low labour costs and now in a trade war with the U.S., could easily redefine the global game, and in a big way, in the years to come.

The Significance of Asian Reform

Asia is widely heralded as the birthplace of medical cannabis. The history of the drug here stretches back millennia, and its use was documented and incorporated into medical texts. It is also thought that the Scythians, travelling bands of nomadic warriors, carried use and knowledge of the drug through Europe.

During the 19thcentury, the drug was commoditized, like tea, by the British East India Company in both China and India. In the 20thcentury, of course, communist anti-drug policies in China tended to follow those in the West, with one critical difference. Drug crimes in this part of the world became associated with even harsher punishments – including the death penalty.

Alone in Asian countries, at least for now, Thailand appears to be ready to step into the export market. The country was, of course, a leading exporter of illegal cannabis during the 1980’s. Now, it appears that the government, like many others around the world, wants to cash in on the multibillion global medical market now exploding in the rest of the world along with reducing an exploding prison population. That said, recreational users will still face harsh penalties.

This is also likely to be the course of reform in other places regionally, including China.

What Does This Mean For Foreign Companies And Investors?

Given the focus on medical use, and remaining draconian fines for recreational use if not “drug trafficking,” foreign entrepreneurs and investors should tread carefully. This is also likely, as a result, to be one of the most complicated places for foreign companies to obtain licenses for production if not ex-im permission.

Added to that, of course, is the likelihood of protectionist measures implemented along with reform, as is likely in Thailand, where the market will be highly protected to preserve both domestic ownership and the benefit to the economy of the same.

It is also highly likely that any foreign investment in such markets, as they liberalize, will be required to partner with local producers.

Regardless, it is clear as 2019 dawns that no part of the world is immune to cannabis reform. The Green Revolution is, five years after market start in Colorado, truly global.

Marguerite Arnold

About Marguerite Arnold

Marguerite Arnold is a veteran investigative and markets journalist, American expat and author. She has covered the cannabis industry from Germany for the last six years. Her book, Green: The First Year of Modern American Cannabis Reform about the American market in 2014 has just been republished as she is writing the sequel about Europe and the global revolution this year. Green II: Spreading Like Kudzu will be published in 2020. She is also a noted technologist and entrepreneur. Her blockchain-based digital prescription platform MedPayRx was just shortlisted by the German Ministry of Health as one of the "Top 20" use cases for blockchain in healthcare.


Network Partners

Follow Us on Social Media

About CFN Media

CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Learn How Your Company can Be Covered on CFN Media

Learn More About the CFN Media Sponsored Content Program

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading